Additionally, semaglutide acts on appetite centres in the brain, helping to reduce hunger and food cravings
Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes
Future Candidates for Retatrutide Once it successfully clears regulatory hurdles, retatrutide may become preferred for: Individuals with severe obesity who have plateaued on dual-agonist or mono-agonist therapies
[1] [2] These medications work by mimicking the action of naturally occurring GLP-1 hormone, which stimulates insulin secretion in response to meals, suppresses glucagon release, slows gastric emptying, and promotes satiety
Lappin G, Noveck R, Burt T
The exact mechanisms underlying these cardiovascular benefits are still being investigated but may involve a combination of improved blood sugar control, weight loss, and direct effects on blood vessels and the heart